These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8744283)

  • 21. Specific cytotoxic effect of neocarzinostatin conjugated to monoclonal antibody A7 on human pancreatic carcinoma.
    Otsuji E; Takahashi T; Yamaguchi T; Yamaguchi N; Imanishi J
    Gastroenterol Jpn; 1990 Apr; 25(2):244-8. PubMed ID: 2140808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NMR studies of the post-activated neocarzinostatin chromophore-DNA complex. Conformational changes induced in drug and DNA.
    Gao X; Stassinopoulos A; Gu J; Goldberg IH
    Bioorg Med Chem; 1995 Jun; 3(6):795-809. PubMed ID: 7582957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel designed enediynes: molecular design, chemical synthesis, mode of cycloaromatization and guanine-specific DNA cleavage.
    Toshima K; Ohta K; Kano T; Nakamura T; Nakata M; Kinoshita M; Matsumura S
    Bioorg Med Chem; 1996 Jan; 4(1):105-13. PubMed ID: 8689230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon induction by SMANCS: a polymer-conjugated derivative of neocarzinostatin.
    Suzuki F; Munakata T; Maeda H
    Anticancer Res; 1988; 8(1):97-103. PubMed ID: 2451896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Solution structure of a novel chromoprotein derived from apo-neocarzinostatin and a synthetic chromophore.
    Urbaniak MD; Muskett FW; Finucane MD; Caddick S; Woolfson DN
    Biochemistry; 2002 Oct; 41(39):11731-9. PubMed ID: 12269815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytotoxicity of smancs in comparison with other anticancer agents against various cells in culture.
    Oda T; Sato F; Yamamoto H; Akagi M; Maeda H
    Anticancer Res; 1989; 9(2):261-5. PubMed ID: 2526613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probing DNA single strands for single-base bulges with neocarzinostatin chromophore.
    Kappen LS; Xi Z; Goldberg IH
    Biochemistry; 2001 Dec; 40(50):15378-83. PubMed ID: 11735421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS: a new rescue cancer chemotherapy.
    Oda T; Yamamoto H; Miki T; Maeda H
    Jpn J Cancer Res; 1989 Apr; 80(4):394-9. PubMed ID: 2526108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of anti-neocarzinostatin (NCS) antibody production in leukemia patients treated with NCS.
    Toki H
    Acta Med Okayama; 1976 Apr; 30(2):135-42. PubMed ID: 135485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Solution NMR structure investigation for releasing mechanism of neocarzinostatin chromophore from the holoprotein.
    Takashima H; Yoshida T; Ishino T; Hasuda K; Ohkubo T; Kobayashi Y
    J Biol Chem; 2005 Mar; 280(12):11340-6. PubMed ID: 15640161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biochemical mechanisms of the DNA cleavage induced by NCS-chromophore].
    Ohtsuki K
    Seikagaku; 1996 Dec; 68(12):1817-24. PubMed ID: 9014491
    [No Abstract]   [Full Text] [Related]  

  • 32. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer.
    Oda T; Maeda H
    Cancer Res; 1987 Jun; 47(12):3206-11. PubMed ID: 2953411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental and clinical studies on the formation of antibodies to neocarzinostatin, a new protein antibiotic.
    Sakamoto S; Maeda H; Matsumoto T; Ogata J
    Cancer Treat Rep; 1978 Dec; 62(12):2063-70. PubMed ID: 156066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular dynamics simulations investigation of neocarzinostatin chromophore-releasing pathways from the holo-NCS protein.
    Zhao X; Wang S; Gao XF; Huang XR; Sun CC
    J Struct Biol; 2010 Jan; 169(1):14-24. PubMed ID: 19747549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo characterization of NcsB3 to establish the complete biosynthesis of the naphthoic acid moiety of the neocarzinostatin chromophore.
    Hang VT; Oh TJ; Yamaguchi T; Sohng JK
    FEMS Microbiol Lett; 2010 Oct; 311(2):119-25. PubMed ID: 20735485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic.
    Maeda H; Takeshita J; Kanamaru R
    Int J Pept Protein Res; 1979 Aug; 14(2):81-7. PubMed ID: 158571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunoresponses and efficacy after arterial infusion of immunoconjugate A7-NCS in patients with colon cancer].
    Honda M; Yamaguchi T; Ohtsuji E; Noguchi A; Chimori Y; Doi M; Kamiguchi M; Noguchi A; Kitamura K; Yokota T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1811-4. PubMed ID: 2143891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH.
    Oda T; Sato F; Maeda H
    J Natl Cancer Inst; 1987 Dec; 79(6):1205-11. PubMed ID: 2961908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetics of neocarzinostatin in patients with malignant glioma. Quantitative analysis of tissue concentration].
    Otsuka T; Matsukado Y; Uemura S; Kuratsu J; Sonoda H; Mihara Y; Goto S
    Neurol Med Chir (Tokyo); 1989 Jun; 29(6):471-5. PubMed ID: 2479848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Comparative study with neocarzinostatin].
    Hirayama S; Sato F; Oda T; Maeda H
    Jpn J Antibiot; 1986 Mar; 39(3):815-22. PubMed ID: 3016359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.